Security Snapshot

Syndax Pharmaceuticals Inc - COMMON STOCK (SNDX) Institutional Ownership

CUSIP: 87164F105

13F Institutional Holders and Ownership History from Q1 2016 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

177

Shares (Excl. Options)

75.59MFull value: 75,594,432 · shares · 30 Sep 2026

Price

$18.80

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
-8,603,256
Value change
-$189,223,660
Number of holders
177
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
89,484,077
SEC-reported price per share
$14.15
Insider filing price
$14.15
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • SNDX - Syndax Pharmaceuticals Inc - COMMON STOCK is tracked under CUSIP 87164F105.
  • 177 institutions reported positions in Q3 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 241 to 177 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $2.36BFull value: $2,363,291,442 · USD · 30 Jun 2026
    to
    $1.39BFull value: $1,392,048,650 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 177 institutions filings for Q3 2026.

Open SEC evidence

Security key

87164F105

13F reference period

Q3 2026

13F holders

177

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
SNDX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Kynam Capital Management, LP 10% $113,571,600 8,520,000 Kynam Capital Management, LP 31 Dec 2024
BlackRock, Inc. 7.8% $89,898,173 6,744,049 BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 6.5% +26% $51,576,091 +$9,897,509 5,581,828 +24% THE GOLDMAN SACHS GROUP, INC. 30 Jun 2025
STATE STREET CORP 5.2% -20% $87,479,634 -$18,899,508 4,653,172 -18% STATE STREET CORPORATION 30 Sep 2026
VANGUARD CAPITAL MANAGEMENT LLC 5% $104,118,860 4,457,143 Vanguard Capital Management 31 Mar 2026
MORGAN STANLEY 2.4% -65% $27,193,373 -$44,284,339 2,040,013 -62% Morgan Stanley 31 Mar 2025
Point72 Asset Management, L.P. 2.3% -54% $46,382,378 -$54,718,581 1,985,547 -54% Point72 Asset Management, L.P. 31 Mar 2026
WELLINGTON MANAGEMENT GROUP LLP 0% $475,628 35,681 Wellington Management Group LLP 28 Feb 2025
As of 30 Sep 2026, 177 institutional investors reported holding
75.59MFull value: 75,594,432 · shares · 30 Sep 2026
shares of Syndax Pharmaceuticals Inc - COMMON STOCK (SNDX). This represents 84% of the company’s total
89.48MFull value: 89,484,077 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
62%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Kynam Capital Management, LP 9.1% 8,150,959 8.5% $153,238,029
GOLDMAN SACHS GROUP INC 6.2% 5,523,284 0.01% $103,837,739
STATE STREET CORP 5.2% 4,653,172 0% $87,479,634
VANGUARD CAPITAL MANAGEMENT LLC 4.4% 3,953,935 0% $74,333,978
BANK OF AMERICA CORP /DE/ 4.2% 3,801,955 0% $71,476,754
DEERFIELD MANAGEMENT COMPANY, L.P. 4.2% 3,779,900 1.1% $71,062,120
Hood River Capital Management LLC 2.9% 2,596,543 0.41% $48,815,008
Eversept Partners, LP 2.7% 2,443,056 2.6% $45,929,453
GEODE CAPITAL MANAGEMENT, LLC 2.6% 2,311,016 0% $43,456,150
KINGDON CAPITAL MANAGEMENT, L.L.C. 2.5% 2,245,000 6.3% $42,206,000
VANGUARD PORTFOLIO MANAGEMENT LLC 2.5% 2,220,646 0% $41,748,145
Elmind Capital, LP 1.8% 1,605,000 7.5% $30,174,000
TWO SIGMA INVESTMENTS, LP 1.6% 1,467,125 0.02% $27,581,950
Woodline Partners LP 1.5% 1,330,805 0.08% $25,019,134
Aisling Capital Management LP 1.5% 1,316,806 8.3% $24,755,953
ALGERT GLOBAL LLC 1.2% 1,113,607 0.25% $20,935,812
Parkman Healthcare Partners LLC 1.2% 1,105,057 1.9% $20,775,072
Catalio Capital Management, LP 1.1% 1,023,510 3.6% $19,241,988
SPHERA FUNDS MANAGEMENT LTD. 1.1% 1,007,278 2.9% $18,936,826
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.96% 862,000 0.02% $16,205,600
Prosight Management, LP 0.91% 812,582 3% $15,276,542
Legal & General Group Plc 0.74% 665,464 0% $12,510,723
VANGUARD FIDUCIARY TRUST CO 0.71% 636,173 0% $11,960,052
Soleus Capital Management, L.P. 0.69% 615,990 0.41% $11,580,612
Apis Capital Advisors, LLC 0.68% 605,000 1.6% $11,374,000

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
43
Headline period
Q3 2026
Rows shown
1-25 of 43
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 75,594,432 $1,392,048,650 -$189,223,660 $18.80 177
2026 Q2 108,102,412 $2,363,291,442 +$182,092,102 $21.86 241
2026 Q1 99,424,387 $2,321,728,426 -$8,245,027 $23.36 246
2025 Q4 99,897,694 $2,098,468,343 -$24,363,545 $21.01 228
2025 Q3 101,125,579 $1,555,833,342 +$19,170,271 $15.38 226
2025 Q2 101,743,087 $952,765,629 -$3,412,831 $9.36 214
2025 Q1 100,841,762 $1,238,937,353 +$32,280,128 $12.28 215
2024 Q4 98,036,463 $1,295,985,057 +$87,204,107 $13.22 214
2024 Q3 88,967,889 $1,713,503,490 +$22,962,287 $19.25 208
2024 Q2 87,359,094 $1,793,463,324 -$71,085,162 $20.53 195
2024 Q1 90,291,619 $2,148,803,982 +$45,990,918 $23.80 188
2023 Q4 88,660,945 $1,915,962,261 +$405,830,138 $21.61 176
2023 Q3 71,017,590 $1,031,468,287 -$1,236,482 $14.52 174
2023 Q2 70,660,286 $1,478,899,897 -$48,383,346 $20.93 165
2023 Q1 72,989,203 $1,541,067,785 +$23,662,697 $21.12 161
2022 Q4 71,468,832 $1,818,847,118 +$262,720,878 $25.45 159
2022 Q3 59,986,014 $1,441,473,166 +$97,845,580 $24.03 136
2022 Q2 55,225,664 $1,062,543,225 +$21,478,133 $19.24 116
2022 Q1 54,572,890 $948,388,792 -$36,428,045 $17.38 136
2021 Q4 52,428,774 $1,146,955,026 +$54,297,905 $21.89 129
2021 Q3 49,078,197 $938,007,416 -$20,732,602 $19.11 121
2021 Q2 50,204,902 $861,938,071 +$12,311,173 $17.17 113
2021 Q1 48,482,656 $1,083,969,550 +$46,478,159 $22.36 130
2020 Q4 46,493,166 $1,034,139,433 +$269,937,051 $22.24 140
2020 Q3 34,234,622 $505,296,990 +$23,535,263 $14.76 98
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .